Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP3 | O14638 | 2/20 | 0.41 |
| ▸ | ALPL | P05186 | 2/20 | 0.41 |
| ▸ | XIAP | P98170 | 2/20 | 0.41 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.36 |
| ▸ | AR | P10275 | 7/20 | 0.36 |
| ▸ | EPAS1 | Q99814 | 5/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14291053 | 0.92 | ENPP3 (0.42) | ENPP3ALPLXIAPENPP1KCNH2 | |
| SCHEMBL4716327 | 0.86 | ENPP3 (0.43) | ENPP3ALPLXIAPENPP1KCNH2 | |
| SCHEMBL4768286 | 0.85 | KCNH2 (0.36) | ENPP3ALPLXIAPKCNH2AR | |
| SCHEMBL14290740 | 0.85 | KCNH2 (0.36) | ENPP3ALPLXIAPKCNH2AR | |
| SCHEMBL14303592 | 0.80 | KCNH2 (0.44) | ENPP3ALPLXIAPENPP1KCNH2 | |
| SCHEMBL508348 | 0.78 | ENPP3 (0.45) | ENPP3ALPLXIAPENPP1KCNH2 | |
| SCHEMBL509286 | 0.78 | EPAS1 (0.40) | ENPP3ALPLXIAPENPP1AR | |
| SCHEMBL14540399 | 0.75 | ENPP3 (0.35) | ENPP3ALPLXIAPENPP1KCNH2 | |
| SCHEMBL4720561 | 0.73 | KCNH2 (0.38) | ENPP3ALPLXIAPENPP1KCNH2 | |
| SCHEMBL509611 | 0.68 | KCNH2 (0.48) | ENPP3ALPLXIAPENPP1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556381-B1 | PYRAZOLE AMIDES FOR TREATING HIV INFECTIONS | PFIZER LTD (GB) | 2008-02-20 | — | — | EP | disclosed |
| US-7157468-B2 | Pyrazole derivatives | PFIZER INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157468-B2 | Pyrazole derivatives | PFIZER INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157468-B2 | Pyrazole derivatives | PFIZER INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-20050004129-A1 | Pyrazole derivatives | PFIZER, INC. | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004129-A1 | Pyrazole derivatives | RTF1, RRM2B, RRM2 | ENPP3 1100/4885ALPL 2537/4885XIAP 3123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.